INTRODUCTION
Streptococcus pneumoniae is the leading cause of bacterial meningitis [1] . The risk of developing pneumococcal meningitis is highest in young children, the elderly and those who are immunocompromised or who suffer from chronic diseases [1] . In a global literature review of children under 5 years of age, the overall incidence rate of pneumococcal meningitis was 17/100,000 (95% CI 8-21), ranging from 6/100,000 (95% CI 5-9) in Europe to 38/100,000 (95% CI 11-48) in Africa [2] . In Europe, before the widespread use of 7-valent pneumococcal conjugate vaccine (PCV7), the highest pneumococcal meningitis rates were reported in children aged \12 months in Spain (17.8/100,000) and in children aged \2 years in Belgium (16.1/ 100,000) [3] . Based on an extensive literature review of publications from 1980 to 2005, the overall case fatality rate (CFR) in children aged \5 years with pneumococcal meningitis was 59% (95% CI 27-80%), ranging from 38% (95% CI 32-58%) in Europe to 73% (95% CI 18-94%) in Africa [2] . Mortality and morbidity rates in patients with pneumococcal meningitis vary by age, pneumococcal serotype and geographical location [4, 5] .
Untreated bacterial meningitis almost always results in death, and even with optimal treatment death and morbidity can occur [4] . Neurological sequelae are relatively common in survivors of meningitis, particularly after pneumococcal meningitis [4] . Sequelae, such as hearing loss, blindness, seizures, hydrocephalus, developmental delays and motor deficits, have been reported in up to 20% of cases of pneumococcal meningitis in Sweden and in 30% of cases in France, implying a lifetime of considerable disability for those who survive due to a preventable health burden [3, 6] . In France, the mortality rate for bacterial meningitis in the pre-vaccination period was highest in very young children; 13.1%, 14.9% and 9.9% for those aged \1 month, 1 to \2 months and 2 to \12 months, respectively, compared with 6.3% in those aged C5 years [7] .
Vaccines have played a pivotal role in reducing the burden of bacterial meningitis. Results from clinical trials with the Haemophilus, pneumococcal and meningococcal conjugate vaccines clearly demonstrate their ability to reduce the incidence of invasive disease, including meningitis [8] . After the introduction of the Haemophilus influenzae type b (Hib) conjugate vaccine, there was a substantial decrease in the incidence of Hib meningitis, while the incidences of pneumococcal and meningococcal meningitis remained stable [6] . leading to an overall net reduction in all-type IPD [9] . To address the increase in non-VT-IPD, higher valency PCVs have been developed and have replaced PCV7 in most national immunization programs [10] .
To obtain a baseline for the measurement of the impact of the higher-valent PCVs on pneumococcal meningitis, we have summarized the data available on the impact of PCV7 on the incidence of all-type and VTpneumococcal meningitis, in those targeted for vaccination and in those not targeted for vaccination (indirect effect) in North America and Western Europe.
METHODS
The data presented here are part of a larger global literature review on the impact of PCV7 on pneumococcal diseases. The search method has been previously described [9] . In summary, on adjusted incidence rates) were provided or could be calculated. The calculation used was [(incidence pre-vaccination -incidence post-vaccination)/incidence pre-vaccination] 9 100.
We excluded publications that reported efficacy (i.e., randomized clinical trials), modeling or health economics studies, studies on specific populations (e.g., those with comorbidities such as HIV-positive, patients with sickle-cell disease) and studies for which the denominator was unknown.
RESULTS
A total of 1,007 publications were identified from the global search, and after two rounds of screening 84 were selected for inclusion in the global literature review (Fig. 1) . The main reasons for exclusion were: cohort study with no comparative group (epidemiology data); modeling or cost-effectiveness studies; only specific patient subgroups; review articles and no incidence data or insufficient data for calculating incidence (mainly missing data for the denominator). From these, 17 articles reporting data on the impact of routine childhood PCV vaccination on the incidence of pneumococcal meningitis were analyzed: 6 from North America; 11 from Western Europe ( Impact on All-Type Pneumococcal
Meningitis in Vaccine-Eligible Populations
The impact of PCV7 vaccination on all-type pneumococcal meningitis in vaccine-eligible populations ranged from -4.5% (in Spain, in one hospital) to -100% (in another Spanish study in the Basque Country and Navarre) with a median of -47.7% (Table 3 ) [1, 11-14, 16, 19, 20, 25] .
Impact on VT-Pneumococcal Meningitis in Vaccine-Non-Eligible Populations
The impact of PCV7 vaccination on VT-pneumococcal meningitis in vaccine-non-eligible populations ranged from ?43.2% (in Spain in subjects aged C18 years, in one hospital) to -87.5% (in US in subjects aged C65 years), with a median of -67.1% (Table 4) [15, 21, 24, 25] . % overall change data were taken from the original publications when available, any observed differences between these and the apparent % overall change based on the incidence data in the table are due to rounding all incidence data to one decimal place and Navarre, in subjects aged\5 years) (Table 5 ) [1, 11, 13, 15-22, 24, 25] . A range of 0% (in France) to -37.5% (in the US), with a median of -25.6%, was reported in five studies that provided data for the impact on all-type pneumococcal meningitis in all ages (Table 5) . % overall change data were taken from the original publications when available, any observed differences between these and the apparent % overall change based on the incidence data in the table are due to rounding all incidence data to one decimal place
Evolution of Non-Vaccine-Type Pneumococcal Meningitis in Vaccine-Eligible and Non-Eligible Populations After PCV7 Introduction
Eight studies reported the evolution of the incidence of non-vaccine-type (NVT)-pneumococcal meningitis in different age groups after PCV7 introduction [11, 12, 14, 15, 19, 21, 24, 25] . The incidence of NVT-pneumococcal meningitis was low in the pre-vaccination period, ranging from 0 in children aged 2-4 years in the US to 5.8/100,000 in children aged \2 years in Belgium [12, 25] . In vaccine-eligible populations, three studies reported an increase of ?104.2% (from 2.4 to 4.9/100,000) in France, ?125.9% (from 5.8 to 13.1/100,000) in Belgium and ?272.7% (from 0.77 to 2.87/100,000) in the US, although the absolute incidence remained low [12, 19, 25] . In children aged 5-17 years in one study in the US, there was no change in the incidence of NVT-pneumococcal meningitis, whereas, overall, in all ages there was a significant 60% increase [25] . In vaccine-non-eligible populations, all studies reported an increase in the incidence of NVT-pneumococcal meningitis, ranging from ?45% in those aged 5-54 years in the UK to ?215.9% (from 0.44 to 1.39/100,000) in all adults in Spain [15, 21] .
In those aged C65 years, in the US, a decrease of -36.7% (from 0.79 to 0.50/100,000) was reported, whereas in another study in the US, an increase of 27.3% (from 1.1 to 1.4/100,000) was reported [24, 25] . In the UK, for this age group, an increase of 20.0% (0.25-0.30/100,000) was reported [21] .
DISCUSSION
There was a substantial reduction in VT-pneumococcal meningitis in both vaccine-eligible and vaccine-non-eligible age groups. While the rate reductions of VT-pneumococcal meningitis were generally similar between different age groups, the % overall change data were taken from the original publications when available, any observed differences between these and the apparent % overall change based on the incidence data in the table are due to rounding all incidence data to one decimal place Calbo et al. [17] pre-PCV7 incidence in children aged \2 years was much higher than in the other age groups so that the relative reduction was greater for this age group. The reduction in VT-pneumococcal meningitis was partially offset by an increase in NVT-pneumococcal meningitis, but generally the increase was not sufficient to prevent an overall reduction; the exceptions to this were generally in the older age groups in studies that were not national (Table 5 ) [13, 15, 18, 20] .
Thus, PCV7 has reduced the incidence of all-type pneumococcal meningitis across all ages, which is a substantial public health benefit.
For the older age groups, the reduction in VT-pneumococcal meningitis is possible evidence of a herd effect. All but one of the studies, in Denmark, reported a reduction in those aged C65 years, ranging from 2.6 to 54.2 (Table 5) . However, these data should be interpreted with caution due to the low incidence of VT and all-type pneumococcal meningitis in these age groups. In addition, there may be some protection through 23-valent pneumococcal polysaccharide vaccine (PPV23) vaccination in the elderly and adults with comorbidities. However, two studies, one in the US (in adults, with and without PPV23 indications) and one in the UK (in those aged C65 years), reported that after PPV23 introduction there was no evidence of a decrease in the incidence of IPD (not just meningitis) caused by serotypes in this [1] .
The incidences of pneumococcal meningitis, both in the pre-vaccination and post-vaccination eras, were variable between the studies. This variability may be due to several factors including under reporting, differences in reporting methods, differences in blood-culture practices and antibiotic prescribing [3] . This emphasizes the need for well organized, robust, surveillance systems to enable the impact of vaccination on IPD, especially pneumococcal meningitis, to be monitored [2, 3, 32] .
The different time periods studied and countries in which the studies were conducted could contribute to the variability, since circulating pneumococcal serotypes show temporal and geographical variations [33] [34] [35] . In addition, the pre-vaccination and post-vaccination periods studied, particularly in relation to the date of PCV7 introduction, can have a significant impact. There were also differences in the introduction of PCV7 in terms of catch-up campaigns, which has an effect on the rapidity of impact. In the studies included in this analysis, there were different vaccination schedules (3 ? 1 and 2 ? 1) used with differing rates of uptake; for example, in the UK, there was rapid uptake after introduction into the NIP with a 2 ? 1 schedule, whereas in Spain there was slow uptake after introduction through the private market with a 3 ? 1 schedule [18, 21, 36] . One limitation of our review is that in the search strategy we used the term 'invasive pneumococcal disease' and not 'meningitis' specifically: to assess the impact of this, we retrospectively performed a search which identified four publications, two from Northern
France (using the same data source but for different periods) and two from Spain (one of which was in Spanish) [37] [38] [39] [40] . Data from a national study in France has already been included [19] . In addition, one other study reporting data from 252 pediatric wards in CONCLUSION PCV7 has had a significant impact on the overall incidence of pneumococcal meningitis, despite an increase in NVT-pneumococcal meningitis. The higher valency vaccines contain many of the serotypes that are now more commonly responsible for pneumococcal meningitis in both children and adults [5] . With the introduction of PCV13 we can expect to see a reduction in the incidence of pneumococcal meningitis due to the additional six serotypes included, as well as continued protection against IPD due to PCV7 serotypes. Robust surveillance systems will be essential for the evaluation of the impact of PCV13 on all-type pneumococcal meningitis and for monitoring the evolution of NVT-pneumococcal meningitis. 
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